Bausch Health (BHC) Lags Q2 Earnings Estimates

Bausch Health (BHC) reported mixed Q2 2025 results, missing Zacks Consensus EPS estimates at $0.90 per share (a -7.22% surprise) but exceeding revenue expectations with $2.53 billion. Despite the earnings miss and a significant 15.4% year-to-date underperformance against the S&P 500, the stock holds a Zacks Rank #2 (Buy) based on prior favorable estimate revisions, suggesting potential for near-term outperformance, though future price movement will hinge on management's commentary and any subsequent analyst estimate changes.

Analysis

Bausch Health reported mixed results for the quarter ended June 2025, demonstrating a divergence between top-line strength and bottom-line performance. The company surpassed revenue expectations by 2.42%, posting $2.53 billion compared to the prior year's $2.4 billion, marking the third revenue beat in the last four quarters. However, adjusted earnings per share of $0.90 missed the Zacks Consensus Estimate of $0.97, representing a -7.22% surprise. This marks the second consecutive quarter of missing EPS targets, following a significant -28.92% surprise in the prior quarter. Despite this earnings weakness and the stock's notable underperformance year-to-date, with shares down 15.4% against the S&P 500's 8.3% gain, Bausch Health carried a Zacks Rank #2 (Buy) into the announcement. This favorable rating was based on positive estimate revisions trends prior to the report, and its sustainability will now depend heavily on management's commentary during the earnings call and subsequent analyst revisions. The company's Medical - Generic Drugs industry is ranked in the top 37% of Zacks industries, providing a moderately positive sector backdrop.

Key Decisions for Investors

• Investors should scrutinize the disconnect between strong revenue performance, which surpassed estimates to reach $2.53 billion, and the repeated earnings misses, indicating potential margin erosion or operational challenges that require explanation.
• It is critical to monitor management's commentary on the earnings call for insights into profitability and future guidance, as this will likely dictate whether the stock can reverse its 15.4% year-to-date decline.
• Consider the current Zacks #2 (Buy) rating with caution, as it was based on pre-release data and may be downgraded following the -7.22% earnings surprise, making upcoming analyst revisions a key indicator to watch.